Silicone Gel-Filled Breast Implants Approved

After rigorous scientific review, the Food and Drug Administration has approved the marketing of silicone gel-filled breast implants made by two companies for breast reconstruction in women of all ages and breast augmentation in women ages 22 and older. The products are manufactured by Allergan Corp. of Irvine, Calif., and Mentor Corp. of Santa Barbara, Calif.

"FDA has reviewed an extensive amount of data from clinical trials of women studied for up to four years, as well as a wealth of other information to determine the benefits and risks of these products," said Daniel Schultz, M.D., director of the FDA's Center for Devices and Radiological Health after the approval in November 2006. "The extensive body of scientific evidence provides reasonable assurance of the benefits and risks of these devices."

Now that the products have been determined to be safe and effective, the FDA will continue to monitor them by requiring each company to conduct a large postapproval study following about 40,000 women for 10 years after receiving breast implants. The FDA often requires postmarket studies to answer important questions that can be answered only once a product is in broader use, such as the incidence of rare adverse events.

The FDA's decision to approve these implants was based on a thorough review of each company's clinical (core) and preclinical studies, a review of studies by independent scientific bodies, and deliberations of advisory panels of outside experts that heard public comment from hundreds of stakeholders.

Some of the complications reported in the core studies included hardening of the area around the implant, breast pain, change in nipple sensation, implant rupture, and the need for additional surgery. The majority of women in these studies, however, reported being satisfied with their implants.

In the past decade, a number of independent studies have examined whether silicone gel-filled breast implants are associated with connective tissue disease or cancer. The studies, including a report by the Institute of Medicine, have concluded there is no convincing evidence that breast implants are associated with either of these diseases. These issues, however, will be addressed further in the postapproval studies conducted by the companies.

The package and patient labeling mandated by the FDA contain full information about the risks and benefits of the devices. The patient labeling outlines some important factors women should consider when deciding whether to get silicone gel-filled breast implants, such as the following:

Breast implants are not lifetime devices, and a woman will likely need additional surgeries on her breast at least once over her lifetime.
Many of the changes to a woman's breast after implantation are irreversible.
Rupture of a silicone gel-filled breast implant is most often silent, which means that usually neither the woman nor her surgeon will know that her implants have ruptured.
A woman will need regular screening Magnetic Resonance Imaging (MRI) examinations over her lifetime to determine whether silent rupture has occurred.

The labeling states that a woman should have her first MRI three years after her initial implant surgery and then every two years thereafter. The cost of MRI screening over a woman's lifetime may exceed the cost of her initial surgery and may not be covered by medical insurance. The labeling also states that if implant rupture is noted on an MRI, the implant should be removed and replaced, if needed.

The FDA approved the silicone gel-filled breast implants with a number of conditions, including requiring each company to

conduct a large postapproval study
continue its core study through 10 years
conduct a focus group study of the patient labeling
continue laboratory studies to further characterize types of device failure
track each implant in the event, for example, that health professionals and patients need to be notified of updated product information.

The postapproval studies will continue to gather information about the safety and effectiveness of the implants. Information will be collected about rates of local complications, rates of connective tissue disease and its signs and symptoms, rates of neurological disease and its signs and symptoms, potential effects on offspring of women with breast implants, potential effects on reproduction and lactation, rates of cancer, rates of suicide, potential interference of breast implants with mammography, and MRI compliance and rupture rates. The FDA will closely monitor the postapproval studies. The agency anticipates that data from the studies will provide important information for patients and physicians, and may lead to improvements in device labeling.

Visit www.fda.gov/cdrh/breastimplants for more information.

horizontal rule